The leading resource for comprehensive insight and
intelligence on the global psychedelics industry.
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic healthcare industry.
The industry’s most engaged event series where trusted thought leaders, active investors and top-tier operators
connect and collaborate.
A media platform for the psychedelic science and healthcare industry
𝗜𝗺𝗽𝗿𝗼𝘃𝗶𝗻𝗴 𝗽𝘀𝘆𝗰𝗵𝗲𝗱𝗲𝗹𝗶𝗰 𝘁𝗿𝗶𝗮𝗹𝘀
🧶Methodological challenges in clinical trials
🎆Mystical experiences x wellbeing in recreational use
🐸Novel 5-MeO-DMT formulation proves safe
🧵Psychedelic Research Briefing 49 '21 📰1/8
As healthcare providers look to embrace psychedelic medicines, @Forbes spoke with Andrew Penn of @UCSF the importance of trained practitioners:
Nurses In Psychedelics, Naturals Caring For Patients In Non-Ordinary States Of Consciousness
Nurses are skilled in holding space as patients endure challenging events in real time and for prolonged periods, ...
In support of psychedelic medicines, the DEA has proposed another surge in production quotas.
The agency now wants 8.2kg of MDMA produced in 2022:
Final 2022 quotas:
💊8.2kg of MDMA
🍄8kg of psilocybin
👤3kg of DMT
🐸2.55kg of 5-MeO-DMT
🚵500g of LSD
DEA Again Boosts 2022 Production Goals For Psychedelics Like Psilocybin, MDMA and DMT
The Drug Enforcement Administration (DEA) has yet again increased its quota for the legal production of illegal cont...
Live from @HorizonsConf we will be reporting on the talks today 'Focus on Clinical Research' 1/many
'We're a biotech company but we have a limited amount of clinics. Those clinics are there so we can test and validate in the real world the therapies we've developed in our clinical research.'
@Awakn_ls' CEO Anthony Tennyson spoke with @MidasLetter: $AWKN
Can Psychedelics Cure Addiction? | Awakn Life Sciences $AWKN $AWKNF
Awakn Life Sciences Corp (NEO:AWKN, OTCMKTS:AWKNF) is a biotechnology company developing new psychedelic therapeutics to b...
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Gain unparalleled market intelligence and insights from thought-leaders and industry experts, identifying lucrative opportunities for investors, operators and regulators.